Literature DB >> 8481982

Levels of fluconazole in serum, stratum corneum, epidermis-dermis (without stratum corneum) and eccrine sweat.

J Faergemann1, H Laufen.   

Abstract

The distribution in the skin of orally active antifungals and other drugs claimed to be active in the treatment of skin diseases is of major importance, but to date has been studied only rarely. In the present study the distribution of fluconazole in stratum corneum, epidermis-dermis (without stratum corneum), eccrine sweat and serum was studied in human male volunteers after dosages of 50 mg daily for 12 days and 150 mg once weekly for 2 weeks. In the present study high levels of fluconazole were found especially in the stratum corneum. At a dose of 50 mg once daily the concentration of fluconazole after 12 days was 73.0 micrograms/g and 7 days after cessation of treatment the concentration was still 5.8 micrograms/g. At the 150 mg once a week dose the concentration 7 days after the second dose was still 7.1 micrograms/g in stratum corneum indicating that medication once a week may be effective in the treatment of dermatomycoses. High concentrations, all above the serum concentrations, were also seen in sweat and epidermis/dermis. These results indicate that fluconazole is delivered to the stratum corneum, where it is accumulated, through sweat and by direct diffusion through the dermis-epidermis. These pharmacokinetic results indicate that the drug should be very effective in the treatment of dermatomycoses. An extremely high concentration of the drug in the stratum corneum combined with concentrations from 2.93 to 4.62 micrograms/g in the rest of the epidermis and dermis is important in the treatment of these diseases.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8481982     DOI: 10.1111/j.1365-2230.1993.tb00987.x

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN: 0307-6938            Impact factor:   3.470


  12 in total

1.  Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses.

Authors:  D Debruyne
Journal:  Clin Pharmacokinet       Date:  1997-07       Impact factor: 6.447

Review 2.  Clinical and economic factors in the treatment of onychomycosis.

Authors:  T R Einarson; A K Gupta; N H Shear; S Arikian
Journal:  Pharmacoeconomics       Date:  1996-04       Impact factor: 4.981

Review 3.  Tinea gladiatorum: wrestling's emerging foe.

Authors:  T D Kohl; M Lisney
Journal:  Sports Med       Date:  2000-06       Impact factor: 11.136

4.  Fluconazole penetration into the pancreas.

Authors:  S Shrikhande; H Friess; C Issenegger; M E Martignoni; H Yong; B Gloor; R Yeates; J Kleeff; M W Büchler
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

Review 5.  Working Up a Good Sweat - The Challenges of Standardising Sweat Collection for Metabolomics Analysis.

Authors:  Joy N Hussain; Nitin Mantri; Marc M Cohen
Journal:  Clin Biochem Rev       Date:  2017-02

6.  In vivo efficacy and pharmacokinetics of voriconazole in an animal model of dermatophytosis.

Authors:  D M Saunte; F Simmel; N Frimodt-Moller; L B Stolle; E L Svejgaard; M Haedersdal; C Kloft; M C Arendrup
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

Review 7.  Treatment and prophylaxis of tinea infections.

Authors:  G E Piérard; J E Arrese; C Piérard-Franchimont
Journal:  Drugs       Date:  1996-08       Impact factor: 9.546

8.  [Modern antimycotics. What the treating physician needs to know].

Authors:  C Seebacher
Journal:  Hautarzt       Date:  2004-02       Impact factor: 0.751

Review 9.  Pharmacokinetic optimisation of oral antifungal therapy.

Authors:  M Schäfer-Korting
Journal:  Clin Pharmacokinet       Date:  1993-10       Impact factor: 6.447

10.  Intracutaneous distributions of fluconazole, itraconazole, and griseofulvin in Guinea pigs and binding to human stratum corneum.

Authors:  Satoshi Sobue; Kaneo Sekiguchi; Toshitaka Nabeshima
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.